MedTrace Logo

An Expanded Clinical Study of Triple Therapy for Refractory Solid Tumors That Failed First-line Treatment for Recurrence and Metastasis

NCT05438342 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 195

Last updated 2022-06-29

No results posted yet for this study

Summary

The clinical efficacy of chemotherapy /PD-1 monoclonal antibody/targeted therapy, chemotherapy /PD-1 monoclonal antibody/targeted therapy + noninvasive electromagnetic wave hyperthermia and chemotherapy /PD-1 monoclonal antibody/targeted therapy + noninvasive electromagnetic wave hyperthermia + autosomatic immunotherapy in the treatment of refractory refractory solid tumors with first-line treatment failure was compared.

Conditions

Interventions

BIOLOGICAL

Autologous Adoptive immune cells

Immunotherapy Mononuclear cells were collected from 50ml peripheral blood , and cultured adoptive immune cells for 15-20 days. Cells were infused back to the patients in 3 times via intravenous infusion.

DEVICE

Thermotron RF-8EX

Hyperthermia for 40-50 minutes

DRUG

Chemotherapy，checkpoint immunotherapy, targeted therapy

The doctor chooses the appropriate systemic treatment for the patient based on NCCN guidelines

Sponsors & Collaborators

Principal Investigators

  • Jun Ren, MD,PhD · Fudan University Pudong Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2023-10-01
Completion
2023-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05438342 on ClinicalTrials.gov